Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity

Atossa Therapeutics, Inc. (NASDAQ:ATOS) is among the best growth stocks to invest in for the next 5 years. Ascendiant Capital analysts slightly increased the price target for Atossa Therapeutics, Inc. (NASDAQ:ATOS) to $7.50, up from $7.25, with an unchanged Buy rating. This potential surge of 837% from current levels reinforces the company’s attractive valuation.

In making their judgment, the analysts noted that the updated price target is the perfect balance between the company’s high risks and its growth prospects. While analyzing the net present value of Atossa Therapeutics, Inc. (NASDAQ:ATOS), the firm pointed towards the company’s impressive liquidity position with a current ratio of 12.67. This is anything but ordinary.

A scientist in a laboratory, working on developing a new cancer therapy.

Despite its associated risks, Atossa Therapeutics, Inc. (NASDAQ:ATOS) exhibits high upside opportunities. Just recently, the company highlighted its strategic moves in breast cancer at the Jefferies Conference. While utilizing Generative AI, Atossa Therapeutics will discover effective drug combinations, along with efforts to capitalize on the multi-billion-dollar market for estrogen receptor-positive breast cancer with Z endoxifen.

Atossa Therapeutics, Inc. (NASDAQ:ATOS) is a Washington-based clinical-stage biopharmaceutical company focused on developing medicines for women’s breast cancer and other oncological conditions. Founded in 2008, the company aims to transform breast cancer treatment through innovative and tailored solutions.

While we acknowledge the potential of ATOS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.